Ignite Creation Date:
2024-05-06 @ 6:01 PM
Last Modification Date:
2024-10-26 @ 2:40 PM
Study NCT ID:
NCT05514119
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2022-08-23
Brief Title:
A Study to Assess the Role of Fenofibrate in Preventing Ischemic Cholangiopathy After Liver Transplantation
Sponsor:
Mayo Clinic
Organization:
Mayo Clinic
Study Overview
Official Title:
Fenofibrate to Prevent Ischemic Cholangiopathy in Donation After Circulatory Death Liver Transplantation FICsDCD
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FICsDCD
Brief Summary:
The purpose of this study is to evaluate the safety and effectiveness of a once-daily medication fenofibrate Lofibra to prevent ischemic cholangiography IC in persons who were transplanted with livers donated after circulatory death DCD
Detailed Description:
In this prospective pilot study we aim to evaluate 1 the tolerability and safety 2 the efficacy of 12 weeks once-daily fenofibrate in reducing IC incidence after DCD liver transplantation 3 assess the association between serum markers of cholestasis and development of IC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None